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Over the last 15 years, considerable work has accumulated to support the role of the CNS
in regulating postprandial glucose levels. As discussed in the first section of this review, the
CNS receives and integrates information from afferent neurons, circulating hormones, and
postprandially generated nutrients to subsequently direct changes in glucose output by the
liver and glucose uptake by peripheral tissues. The second major component of this review
focuses on the effects of external pressures, including high fat diet and changes to the
light:dark cycle on CNS-regulating glucose homeostasis. We also discuss the interaction
between these different pressures and how they contribute to the multifaceted mechanisms that we hypothesize contribute to the dysregulation of glucose in type 2 diabetes
mellitus (T2DM). We argue that while current peripheral therapies serve to delay the progression of T2DM, generating combined obesity and T2DM therapies targeted at the CNS,
the primary site of dysfunction for both diseases, would lead to a more profound impact
on the progression of both diseases.
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INTRODUCTION

CNS CONTROL OF GLUCOSE HOMEOSTASIS

Homeostasis refers to the process of maintaining basic physiological functions despite changes in the internal or external
environment. This review will focus specifically on glucose homeostasis, which is the ability to maintain steady blood glucose levels
(within 90–120 mg/dl) in spite of nutrient ingestion (feeding vs.
fasting), stress (mental or physical), or other environmental challenges. Historically, the role of the CNS in regulating glucose
has largely focused on the role of the autonomic nervous system (ANS) in defending against falling glucose levels (glucose
counter regulation). However, a large body of work has accumulated over the last 15 years supporting the role of the CNS
in regulating postprandial glucose levels. To do this, the CNS
must sense and integrate information stemming from the activity of afferent neurons, and postprandial increases in circulating
hormones and nutrients. The CNS then responds by increasing
autonomic efferent activity to direct changes in glucose output
by the liver and glucose uptake by peripheral tissues (Obici et al.,
2002b,c, 2003; Lam et al., 2005a,b,c; Pocai et al., 2005a,c; Sandoval et al., 2008a). The first section of this review will focus on
the various signals that act within the CNS to regulate glucose
homeostasis. The second section of this review will then focus
on the external pressures, including high fat diet, changes to the
light:dark cycle, as well as the interaction between these different pressures that contribute to the multifaceted mechanisms that
we hypothesize contribute to the dysregulation of glucose in type
2 diabetes mellitus (T2DM). Lastly, we argue that while current
peripheral therapies serve to delay the progression of T2DM, if we
could generate combined obesity and T2DM therapies targeted
to the CNS, a primary site of dysfunction for both diseases, the
impact on the progression of both diseases could be much more
profound.

While the CNS is integral to normal glucose homeostasis, it is
important to recognize the peripheral responses to nutrient ingestion as well. This is reviewed in Figure 1 and illustrates the wide
array of physiological signals (glucose, GLP-1, insulin, etc.) that
are increased postprandially to regulate the balance between liver
glucose production and skeletal muscle glucose uptake with the
goal of maintaining steady plasma glucose levels. While there are
certainly examples of CNS manipulations that regulate insulin
secretion or skeletal muscle uptake, the predominant literature
suggests that CNS regulates glucose homeostasis via changes in
hepatic glucose production (HGP).
Much of what we know regarding the neurocircuitry that regulates glucose homeostasis has been extended from the known
neurocircuitry regulating energy homeostasis. The paraventricular nucleus (PVN), the ventromedial hypothalamus (VMH), the
lateral hypothalamus, and specific neurons within the hindbrain
have all been shown to regulate both energy and glucose homeostasis. However, the role of the arcuate nucleus (ARC) on regulating
both energy and glucose homeostasis is the most widely studied.
Neurons within the ARC that express the anabolic peptides, neuropeptide Y (NPY) and Agouti-related peptide (AgRP), and the
catabolic peptide proopiomelanocortin (POMC; Sandoval et al.,
2008b) have specific and important roles in regulating energy and
glucose homeostasis. Their role in regulating energy homeostasis
is reviewed in Figure 2. In this section we discuss the impact of
endocrine and nutrient signals that work via the CNS, primarily
via ARC neurons to regulate glucose homeostasis.
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ENDOCRINE: INSULIN AND LEPTIN

As illustrated in Figure 1, insulin is essential for the regulation
of glucose homeostasis by acting directly on insulin receptors
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FIGURE 1 | Peripheral control of glucose homeostasis. After nutrient
ingestion, glucose is absorbed and distributed in equal thirds to the liver,
skeletal muscle and adipose tissue, and to remaining tissues including the
CNS. The liver both stores (the storage form of glucose is glycogen) and
produces glucose that is distributed to the body. Hepatic glucose production is
dictated by two metabolic pathways, glycogen lysis (breakdown of glycogen)
and gluconeogenesis (production of glucose from non-glucose precursors
such as lactate and alanine). Other organs in the body also store glycogen but
the amount is miniscule compared to the liver and skeletal muscle. Of the
postprandial distribution of glucose, only glucose uptake into the skeletal
muscle and adipose tissue is dependent on the increases in insulin released

within the liver and skeletal muscle. Insulin, in addition to the
adipokine leptin, circulate in proportion to body fat (Caro et al.,
1996; Considine et al., 1996) and thus serve to inform the CNS
about the current amount of body fat in order to regulate longterm energy stores. Both circulating leptin and insulin penetrate
the blood-brain barrier and bind to their receptors located in
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from the pancreas. The role of the intestine in regulating nutrient partitioning
is highlighted by the fact that pancreatic β-cell insulin secretion in response to
a given glucose load is greater when the glucose is infused into the gut
versus when infused intravenously. This is because, incretins,
glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like
peptide-1 (GLP-1), released from the intestine in a nutrient-dependent
manner, act on their receptors located in the β-cell to stimulate the release of
insulin. GLP-1 also inhibits glucagon secretion. This change in hormonal milieu,
increased insulin, and decreased glucagon levels, have a potent impact on
suppressing hepatic glucose production (HGP), and favoring peripheral
glucose uptake effectively limiting postprandial glycemic excursions.

several brain regions including in the ARC (Van Houten et al.,
1979, 1980; Tartaglia et al., 1995). While insulin acts centrally to
regulate energy homeostasis, it acts both centrally and peripherally
to regulate glucose homeostasis. Indeed, mice with genetic deletion of neuronal insulin receptors are insulin resistant (Bruning
et al., 2000). Even more specific, activation of insulin receptors
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FIGURE 2 | The role of the arcuate nucleus (ARC) in energy balance.
The ARC has two widely studied neuronal populations that regulate both
energy and glucose homeostasis: neurons that express the anabolic
peptides, neuropeptide Y (NPY) and Agouti-related peptide (AgRP), as well
as the catabolic peptide, proopiomelanocortin (POMC). POMC neurons
release α-melanocyte-stimulating hormone (α-MSH) which binds to
melanocortin receptors located on second-order neurons within the
paraventricular, dorsomedial, and ventromedial nuclei and the lateral

within the ARC have a very potent effect on suppressing HGP by
reducing both gluconeogenesis and glycogenolysis (Obici et al.,
2002c) and this effect is independent of its effect on regulating
food intake (Obici et al., 2002a).
Given the importance of insulin receptors on POMC and
NPY/AgRP neurons in energy homeostasis (Schwartz et al., 2000),
it is logical to propose that insulin receptors located on these neurons also have a role in regulating glucose homeostasis. However,
genetic deletion (Konner et al., 2007) or reactivation (Lin et al.,
2010) of insulin receptors specifically on POMC neurons does not
alter hepatic insulin sensitivity in a way that can be separated from
its impact on energy expenditure. These data are consistent with
data demonstrating that melanocortin receptor antagonists delivered into the third cerebral ventricle do not block the ability of central insulin to reduce HGP (Obici et al., 2001). Conversely, when
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hypothalamus. Subsequently, these neurons project to the hindbrain and
the periphery, providing a route of communication between the
hypothalamus and the periphery via autonomic, neurohumoral, and
somatomotor responses. Fasting increases NPY and AgRP expression,
consistent with their role as anabolic effectors and feeding increases
POMC expression. The response of these circuits to the changing status
of stored and ingested nutrients reflects their role in integration of shortand long-term regulation of energy homeostasis.

insulin receptors are selectively removed or reactivated specifically
within AgRP neurons, hepatic insulin sensitivity is respectively
impaired or improved (Konner et al., 2007). Thus, insulin receptor signaling on “anabolic,” but not “catabolic,” neurons improves
glucose homeostasis. AgRP neuronal activity is inhibited by insulin
suggesting that the inhibitory action of insulin on AgRP neurons is responsible for insulin-induced improvements in HGP.
Thus, insulin resistance within AgRP neurons could remove a
major inhibitory signal to these neurons ultimately contributing
to impaired hepatic insulin sensitivity.
When administered centrally, leptin also regulates glucose
homeostasis but in a slightly more complicated manner; via the
ARC (German et al., 2009) leptin decreases glycogenolysis, but
increases gluconeogenesis thus resulting in no net change in HGP
(Liu et al., 1998; Pocai et al., 2005b). Like insulin, leptin action on
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POMC and AgRP neurons is integral in its influence on glucose
homeostasis. The hepatic insulin resistance seen in leptin receptor
null mice is normalized by genetic reactivation of leptin receptors
specifically in POMC neurons in a weight-independent fashion
(Berglund et al., 2012). However, pharmacological antagonism
of melanocortin receptors only inhibits leptin-induced increases
in gluconeogenesis with no effect on glycogenolysis (GutierrezJuarez et al., 2004), suggesting that leptin’s action on regulating
hepatic glucose fluxes is only partly mediated via the melanocortin
system. Given the impact of insulin signaling on AgRP neurons,
it would be interesting to understand the coordinated impact of
leptin receptors on both sets of neurons.
Being an integrated system, it is not surprising that insulin and
leptin signaling converge on POMC neurons to regulate glucose
homeostasis. While deletion of leptin receptors from POMC neurons results in obesity, this effect is partially prevented when both
leptin and insulin receptors are deleted from these neurons yet,
these double-knockout mice have a greater impairment in insulin
tolerance and hepatic insulin resistance compared to control animals (Hill et al., 2010). However, insulin and leptin receptors are
not co-localized to the same individual POMC neuron (Williams
et al., 2010). Instead, some POMC neurons express the leptin
receptor and some express the insulin receptor, suggesting that
these signaling pathways interact between, rather than within,
POMC neurons.
Insulin and leptin receptors are also located within the VMH.
Leptin signaling initiates its own negative feedback loop via a
protein called suppressor of cytokine signaling (SOCS3). Genetic
inactivation of SOCS3 specifically within steroidogenic factor-1
(SF-1) neurons that are primarily expressed within the VMH,
reduces both food intake and energy expenditure leading to no
differences in body weight compared to control animals, but also
normalizes high fat diet-induced hyperinsulinemia (Zhang et al.,
2008a). Further, insulin receptors genetically deleted from SF-1
neurons results in a mouse that is resistant to diet-induced obesity
and diet-induced leptin resistance (Klöckener et al., 2011) and has
reduced hyperinsulinemia with improved systemic glucose and
insulin tolerance. Thus, both insulin and leptin signaling within
the VMH are important for regulating glucose homeostasis.
To summarize, both insulin and leptin act on POMC, AgRP, and
VMH neurons to regulate glucose homeostasis but in a complicated manner. Alone, insulin’s inhibitory action on AgRP, but not
POMC, neurons is necessary for the regulation of glucose homeostasis. Insulin and leptin both act individually on SF-1 neurons,
but have additive action on POMC neurons to regulate glucose
homeostasis. These data highlight the wide array of neurocircuitry that mediate insulin and leptin action, and bring to light
the possibility that insulin and/or leptin resistance that occurs
with the progression toward T2DM at any of these circuits could
significantly impact glucose homeostasis.
NUTRIENT SIGNALING

In addition to hormonal signals like leptin and insulin, the CNS is
responsive to nutrient derived signals. Both glucose (Levin, 2006)
and lipids (Wang et al., 2006) directly regulate neuronal activity
within the ARC, VMH, and nucleus of the solitary tract by either
increasing or decreasing neuronal depolarization. Further, direct
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administration of nutrients or nutrient metabolites such as glucose, lactate, long-chain fatty acids, or leucine into the ARC all
suppress HGP (Obici et al., 2002c; Lam et al., 2005b; Su et al.,
2012). All of these nutrient signals converge on various signaling pathways to modulate neuronal activity and, consequently,
physiology.
The energy currency for all cells when nutrients are metabolized is adenosine triphosphate (ATP). Some membrane potassium
channel activity (opening vs. closing of the channel) is directly
regulated by ATP levels (Parton et al., 2007) and this is used as an
important signaling mechanism. One of the most widely characterized ATP-sensitive potassium (KATP ) channels is found in pancreatic β-cells where glucose metabolism generates ATP leading
to KATP channel depolarization and eventually insulin exocytosis.
Interestingly, neuronal activity in certain neurons within the ARC,
VMH, and NTS is also regulated by KATP channel depolarization
(Levin et al., 2004). Within the ARC, pharmacologically depolarizing KATP channels blocks the ability of glucose, fatty acids, insulin,
or leucine to suppress HGP in rodents (Obici et al., 2002c; Lam
et al., 2005b; Su et al., 2012). Genetic disruption of KATP channels
specifically in POMC neurons impairs glucose-sensing but does
not alter the response of these neurons to leptin, and while these
mice have normal body weights, they have impaired glucose tolerance (Parton et al., 2007). Surprisingly, mice with dysfunctional
KATP channels within melanin concentrating hormone neurons,
orexigenic neurons within the lateral hypothalamus, have normal
body weights but impaired glucose tolerance (Kong et al., 2010).
Thus, hypothalamic KATP channels within the ARC and lateral
hypothalamus are a common mechanism through which different types of nutrients (and insulin but not leptin) and neurons
regulate glucose homeostasis.
Two other intracellular signaling pathways that have important roles in monitoring cellular nutrient status also play a role
in regulating hypothalamic nutrient sensing and consequently
whole-body energy and glucose homeostasis. AMP-activated protein kinase (AMPK) is activated by low ATP levels, and mammalian
target of rapamycin (mTOR) is activated by a surplus in ATP.
Increases in hypothalamic AMPK drives increases in food intake
(Minokoshi et al., 2004), and shifts glucose from the liver to the
muscle by increasing HGP and muscle glycogen synthesis (Perrin
et al., 2004). Genetic disruption of AMPK specifically in POMC or
AgRP neurons causes obesity or resistance to obesity, respectively
(Claret et al., 2007), while the neurons themselves maintain the
ability to respond to insulin and leptin but not glucose. This alteration in body weight confounds the interpretation of this signaling
pathway on regulating glucose homeostasis as changes in body
weight independently regulate glucose homeostasis. However, the
data do suggest that these neurons have an important impact on
body weight regulation but that leptin and insulin act on these
neurons via non-AMPK dependent pathways (Claret et al., 2007).
Mammalian target of rapamycin is a ubiquitously expressed
kinase involved in determining cell growth. Consequently, mTOR
expression within the hypothalamus is increased after feeding and
decreased after fasting (Cota et al., 2006). Leucine administered
into the CNS suppresses food intake via activation of the hypothalamic mTOR pathway (Cota et al., 2006), yet the ability of leucine
to suppress HGP is instead mediated by KATP channel rather than
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mTOR activation (Su et al., 2012). Although presumably independent of leucine, hypothalamic mTOR is still important for
regulating glucose homeostasis. Chronic activation of the TOR
pathway within the ARC reduces diet-induced obesity (Blouet
et al., 2008), but conversely increases HGP at time points where
there is minimal changes in body weight (Ono et al., 2008). Thus,
energy surplus sensed by the hypothalamus activates the mTOR
pathway and subsequently leads to a reduction in body weight but
an increase in hepatic glucose production (HGP). These divergent
effects may depend on the duration of activation and may represent a mechanism to shift fuels to skeletal muscle. Furthermore
these data demonstrate that the regulation of body weight can be
dissociated from the regulation of glucose homeostasis.
Thus far we have discussed how hypothalamic neurons sense
overall energy status by monitoring ATP levels. However, molecular mechanisms exist that allow for sensing of specific types of
fuel. For example, various fatty acids serve as ligands for peroxisome proliferator activated receptors (PPAR). One specific isoform
is PPARγ, a nuclear transcription factor which functions to direct
lipid storage to adipose tissue and away from the liver and skeletal
muscle as fat accumulation in these organs would impair insulin
sensitivity. Clinically, PPARγ agonists (thiazolidinediones) effectively treat hyperglycemia in T2DM but also cause weight gain.
Interestingly, PPARγ is expressed in the CNS, and in rats, both
CNS administration of a PPARγ agonist, or viral induction of
hypothalamic PPARγ expression (Ryan et al., 2011) increase body
weight suggesting that the clinical side effect is via the CNS. On
the other hand, mice that lack PPARγ specifically within the CNS
are resistant to dietary-induced obesity and do not increase feeding or show improvements in hepatic insulin sensitivity when
administered PPARγ agonists (Lu et al., 2011). Thus, CNS PPARγ
activation has a potential role in the regulation of adiposity, is
responsible for the clinical increase in body weight, and at least
partially regulates the improvements in glucose homeostasis seen
with thiazolidinediones.
There is some evidence that the neuronal control of the glucose homeostasis could be aided by specialized glia cells called
tanycytes. The tanycyte cell body lines the third ventricle of the
hypothalamus and a subset of tanycytes (α1 and α2) project to
the ARC and ventromedial hypothalamic nucleus (VMH). It is
hypothesized that glucose levels in the CSF can be detected by the
tanycyte and this information is used to maintain glucose levels
(Rodríguez et al., 2005). The process by which this happens is proposed to be similar to pancreatic β cells for which glucose-sensing
is key to the function of the cell. For example, tanycytes express glucose transporters (Peruzzo et al., 2000; García et al., 2003) and use
the metabolism of glucose to generate ATP and subsequently modulate cellular depolarization (Dale, 2011; Frayling et al., 2011). One
could hypothesize that if these cells are key to regulating glucose
homeostasis then they may be upstream of hypothalamic nuclei
known to regulate HGP and/or glucose uptake. While these cells
clearly sense glucose and it is interesting to propose that they play a
role in regulating glucose homeostasis, this is entirely speculative.

CNS-induced regulation of glucose homeostasis. POMC neurons
that project to the PVN can release GABA, an inhibitory neurotransmitter, or α-MSH, an agonist for PVN-expressed MC4R. An
interesting question is whether MC4R are downstream of POMC
activation in regulation of glucose homeostasis. MC4R alone are
clearly important for glucose homeostasis as demonstrated by
the fact that MC4R knockout mice are hyperinsulinemic prior
to the onset of obesity (Huszar et al., 1997) and have hepatic
and peripheral insulin resistance (Rossi et al., 2011). In addition,
chronic ICV administration of an MC4R agonist improves, while
an MC3/MC4R antagonist impairs, hepatic, and skeletal muscle
insulin sensitivity in a weight-independent fashion (Obici et al.,
2001).
One example that supports MC4R are downstream of POMC
activation is serotonin (5HT). 5HT is synthesized in the dorsal
raphe nucleus of the midbrain and is released into the hypothalamus, including the ARC (Kiss et al., 1984) where it binds to
type 2C receptors (5HT2c ; Heisler et al., 2002). 5HT2C null mice
have increased body weight and hepatic insulin resistance and
reactivation of 5HT2C receptors specifically in POMC neurons
normalizes hepatic insulin sensitivity (Xu et al., 2010) suggesting
that these specific receptors are sufficient to regulate energy and
glucose homeostasis. Although deletion of both leptin and the
5HT2C receptors have additive and weight-independent impairments in fasting glucose and glucose tolerance (Wade et al., 2008),
the data indicate that this is mediated via separate populations
of POMC neurons (Sohn et al., 2011). Interestingly, MC4R null
mice do not respond to pharmacological activation of 5HT signaling, and MC4R reactivation specifically within the PVN and
amygdala restores the effect (Xu et al., 2010) suggesting that the
effect of POMC activation is via MC4R. While it is true that MC4R
do not seem to be downstream of insulin action within the CNS
to regulate glucose homeostasis (Obici et al., 2001), MC4R are
downstream of 5HT activation and at least partially downstream
of leptin.

HYPOTHALAMIC MC4R

GUT-BRAIN-LIVER AXIS

Thus far, we have discussed several pieces of data demonstrating
that the ARC POMC and/or NPY/AgRP neurons are important for

The gut is an important barrier to exogenous nutrients entering the circulation. When exposed to nutrients, not only is there
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HINDBRAIN MC4R

Proopiomelanocortin neurons and MC4R are also expressed
within the hindbrain, and recent data demonstrate their importance in regulating glucose homeostasis (Rossi et al., 2011). Reactivation of MC4R specifically in cholinergic preganglionic sympathetic and parasympathetic neurons located in the dorsal motor
nucleus of the vagus (DMV) attenuates obesity and hepatic, but
not skeletal muscle, insulin resistance seen in MC4R null mice
(Rossi et al., 2011). However, when MC4R were only reactivated in parasympathetic neurons (afferent neurons located in the
nodose ganglia) the only effect was attenuation of hyperinsulinemia (Rossi et al., 2011). Together, these data suggest that MC4R
signaling within the parasympathetic nervous system is important
in specifically regulating insulin secretion but not overall glucose
homeostasis. Lastly, while MC4R located within the hypothalamus
and hind brain regulate glucose homeostasis, it remains unknown
if these systems are integrated in glucoregulation.
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an increase in neuronal activity in vagal afferents that project
directly to hindbrain sympathetic neurons (DiRocco and Grill,
1979), but there is also an intestinal release of several hormones,
neuropeptides, and neurotransmitters that relay changes in nutritional status to the rest of the body. Evidence suggests that two
particular gut peptides secreted postprandially, cholecystokinin
(CCK) and glucagon-like peptide-1 (GLP-1), have action via vagal
afferents to regulate glucose homeostasis forming a gut to brain to
liver axis.
Cholecystokinin is secreted from the proximal intestine in
response to lipid ingestion and functions to regulate satiety, digestion, and gastric emptying. CCK receptors are found on vagal
afferent axons where its action on satiety is mediated (Strader
and Woods, 2005). Recent work suggests that these receptors also
regulate HGP. Infusion of a small amount of lipids sufficient to
increase CCK but with limited impact on plasma triglycerides
(Wang et al., 2008) or a direct infusion of CCK (Cheung et al.,
2009) into the upper intestine of rats suppresses HGP. N -methyld-aspartate channels in the dorsal vagal complex of the hindbrain
(Lam et al., 2010) play an important role in relaying these signals
from the gut to the hindbrain and eventually back to the liver to
regulate HGP.
Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted
postprandially from the distal small intestine. Initially studied for
its important role in insulin secretion and thus glucose homeostasis, GLP-1 is now known to have a wide array of physiological
effects including lipid homeostasis and cardiovascular function
(Drucker, 2006). GLP-1 is also produced within the hindbrain
where it is thought to regulate food intake and visceral illness
(Barrera et al., 2011).
Peripherally secreted GLP-1 likely has limited endocrine action
as it has a short circulating half-life due to rapid degradation (Kieffer and Habener, 1999). However, GLP-1 receptors are located
on afferent neurons that innervate the hepatic portal vein (Vahl
et al., 2007) and on enteric neurons within the gastrointestinal
tract (Amato et al., 2010). These afferent neurons within the portal vein are important for regulating glucose tolerance (Vahl et al.,
2007) and meal patterns (Ruttimann et al., 2009). In addition, both
intravenous GLP-1 in humans (Prigeon et al., 2003), and GLP-1
administered directly into the ARC in rats (Sandoval et al., 2008a)
decrease HGP. Furthermore, intracerebroventricular administration of GLP-1 in rats also stimulates insulin secretion (Knauf et al.,
2005; Sandoval et al., 2008a). We postulate that GLP-1 secreted by
the intestine activates afferent neurons which then activate the
CNS to in turn suppress HGP. Together these data suggest a coordinated response of intestinal and portal vein afferent neurons in
response to postprandially secreted CCK and GLP-1 leading to
efferent activity to the liver via the CNS and thus the regulation of
glucose production by a gut to brain to liver axis.
NEUROANATOMY OF THE CNS TO PERIPHERAL ORGANS

The ANS plays an integral role in regulating peripheral glucose
homeostasis at the liver, muscle, and even indirectly by regulating
pancreatic hormone secretions. The ANS consists of the parasympathetic and sympathetic branches. The parasympathetic branch
is activated postprandially; its effects being mediated primarily
by the vagus nerve which innervates organs of the visceral cavity
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and thus, impacts nutrient digestion, absorption, and metabolism.
Several studies, primarily from one group, have demonstrated
that the hepatic branch of the vagus is essential for the ability
of insulin and nutrients infused directly into the CNS to suppress HGP (Lam et al., 2005a; Pocai et al., 2005a,c; Cheung et al.,
2009). Acetylcholine is the main neurotransmitter released from
vagal efferent neurons, and given the previously described role of
the vagus, it is surprising that neither specific over-expression or
reduction of expression of hepatic M3 receptors impacts normal
regulation of HGP in mice (Li et al., 2009). The authors postulated
that other neurotransmitters co-released with acetylcholine from
vagal terminals (e.g., vasoactive intestinal polypeptide, gastrinreleasing peptide, pituitary adenylate cyclase-activated peptide,
and nitric oxide) are responsible for linking the CNS to regulation
of HGP. Indeed, in isolated hepatocytes, nitric oxide has potent
inhibitory effects on hepatic gluconeogenesis (Horton et al., 1994),
but nothing is known about its role in vivo.
Conversely, the sympathetic branch is activated in times of
physiological stress including exercise and hypoglycemia. Its primary neurotransmitters, norepinephrine, and epinephrine, act on
the liver to increase glucose production and on skeletal muscle to
decrease glucose uptake in order to maintain glucose levels. On
the other hand, the sympathetic nervous system plays a prominent role in hindbrain MC4R-induced suppression of HGP (Rossi
et al., 2011). Like most organs regulated by the ANS, the balance
between parasympathetic and sympathetic activity to the liver is
likely important. It is possible that with the various experimental
models there is a shift in the importance of one of the limbs of
the ANS. Conversely, given the importance of HGP to physiological function, signals processed by the ANS could lead to a hepatic
outcome that results from the integration of the signals involved
in reflecting nutrient status.

ENVIRONMENTAL CHALLENGES TO THE CNS CONTROL OF
GLUCOSE METABOLISM
In the preceding section we discussed several genetic and pharmacological manipulations that impair glucose homeostasis. This
basis allows for the exploration of CNS mechanisms that regulate
glucose homeostasis. However, chronic environmental challenges
such as consumption of high fat diets and a non-stop 24 h society
both place a homeostatic challenge on the CNS. This leads to a
key question of whether these circuits that regulate glucose homeostasis become dysfunctional in the face of these chronic environmental challenges and whether this dysfunction contributes to the
onset or progression of T2DM. In the following section, we discuss
how high fat diets and circadian rhythms can influence the CNS
control of glucose metabolism.
HIGH FAT DIETS

The consumption of a diet high in fat leads to defective hormonal
and nutrient sensing within peripheral organs. This in turn contributes to metabolic dysregulation, including insulin resistance
that occurs as a hallmark of T2DM. However, the CNS is not
immune to the effects of high fat diet. The reduced hormonal and
nutrient sensing that occurs within the CNS impairs CNS-induced
regulation of both energy and glucose homeostasis. Specifically,
high fat diets rapidly and independent of adiposity reduce the

February 2013 | Volume 7 | Article 20 | 6

Arble and Sandoval

ability of ICV insulin, leptin, and fatty acids to reduce food intake
and HGP (Arase et al., 1988; El-Haschimi et al., 2000; Wang et al.,
2001; Morgan et al., 2004; Woods et al., 2004).
The mechanism for this effect is unknown but there is evidence of impaired transport of both leptin and insulin across the
blood-brain barrier (Stein et al., 1987; Israel et al., 1993; Banks
et al., 1999; Banks, 2008). Similarly, both leptin (Banks et al.,
1996) and insulin (Stein et al., 1983; Israel et al., 1993) receptor expression is decreased within the CNS in obesity. However,
impairments are also found within the respective signaling pathways (El-Haschimi et al., 2000; Munzberg et al., 2004). Activation
of hypothalamic inflammatory pathways, which occurs on a high
fat diet, also causes insulin and leptin resistance (Zhang et al.,
2008b; Ozcan et al., 2009) suggesting a linkage between high fat
diets and intracellular events that block insulin and/or leptin signaling. Impairments in neuronal circuitry downstream of the ARC
are also found as MC4R are resistance to pharmacological activation in animals exposed to a high fat diet (Clegg et al., 2003). One
intriguing aspect of CNS leptin signaling is that while the anorectic action of leptin is blunted on a high fat diet, central infusion of
leptin still lowers gluconeogenesis and overall HGP (Morton et al.,
2005; Pocai et al., 2005b) independently of insulin levels (German
et al., 2011).
Expression of a specific component of the KATP channel (Kir6.2
subunit) is reduced in the ventromedial and dorsomedial hypothalamus in pre-diabetic compared to non-diabetic zucker rats
(Gyte et al., 2007) highlighting that hypothalamic nutrient sensing
is also dysfunctional in obesity and could contribute to obesityinduced T2DM. However, more research is needed to determine
what specific neurocircuits are defective in obesity and/or with
high fat diet exposure. A better understanding these impairments
could help elucidate the underlying etiology of obesity and T2DM.
CIRCADIAN RHYTHMS

Many organisms have evolved to predict daily environmental
changes and incorporate 24 h rhythms within their physiology.
These daily rhythms are known as circadian (from the Latin circa
meaning “around” and diem meaning “a day”) and encompass a
broad range of behavioral and physiological characteristics from
the sleep-wake cycle to hormonal fluctuations. Arguably, synching
metabolic rhythms to the light:dark cycle is greatly beneficial to
an organism. This synchronization allows for optimal energy balance tailored to the organisms’ active state as well as an increase
in activity and the recruitment of various meal-related hormones
(e.g., insulin) prior to a meal.
Just as the ARC is central to regulating postprandial glucose levels, the bilaterally paired, suprachiasmatic nuclei (SCN), located
in the anterior hypothalamus, orchestrates circadian rhythms. The
SCN derives “time of day” information from environmental light
cues and relays this timing information to other areas of the CNS
and periphery as depicted in Figure 3. Determining the exact role
of the SCN brain clock on overall glucose metabolism is complex.
While the SCN is the master oscillator of all rhythms, a number
of experiments have shown that altering rhythms downstream of
the SCN, such as the rhythm of peripheral tissue circadian genes
(Panda et al., 2002a; Kornmann et al., 2007; Lamia et al., 2008;
Marcheva et al., 2010; Zhang et al., 2010) or meal timing (Arble
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et al., 2010) can affect glucose metabolism. For this review, we will
focus on the aspects of circadian control of glucose metabolism
that have demonstrated to be regulated more by the SCN master
clock rather than by peripheral rhythms or other behaviors.
The PVN is a common nuclei downstream of both the SCN
and the ARC. Dissimilar to the ARC however, rhythmic release of
GABA from the SCN, rather than α-MSH, onto parasympathetic
PVN neurons regulates circadian fluctuations of glucose metabolism (Kalsbeek et al., 2011). Indeed, via the SCN, all three key
end organs (e.g., pancreas, liver, muscle) exhibit daily changes in
glucose regulation.
Within a healthy individual, plasma glucose exhibits a clear circadian rhythm with a rise just before the beginning of the active
phase (Stenvers et al., 2012). Glucose tolerance also varies over of
24 h period. Notably, the glucose response to a standardized meal
is substantially lower in the morning compared to the afternoon or
evening (Van Cauter et al., 1992; Biston et al., 1996). In humans,
but not nocturnal rodents, plasma insulin levels display a circadian rhythm with more pancreatic insulin production occurring
in the morning than the evening (Baker and Jarrett, 1972; Carroll and Nestel, 1973; Sensi et al., 1973). This rhythm is reversed
in nocturnal rodents. Skeletal muscle glucose uptake is highest in
the morning via both insulin dependent (Verrillo et al., 1989) and
insulin independent (Feneberg and Lemmer, 2004) mechanisms.
While all of these changes would seem to explain the improved
glucose tolerance, HGP also displays its own circadian rhythm.
Indeed, HGP rises during the active period and decreases during
sleep (Clore et al., 1989). Thus, at the start of the active period in
humans, HGP is comparatively low while insulin production and
skeletal muscle glucose uptake are high. Together these changes
can account for the improved glucose tolerance to a morning meal.
Importantly, SCN induced changes in HGP occur independently
of insulin, glucagon, meal timing, and local liver clocks (Cailotto
et al., 2005). The SCN maintains these daily rhythms (la Fleur et al.,
2001) and changes in glucoregulation via innervation of the PVN
and the ANS (Kalsbeek et al., 2004; Cailotto et al., 2008). Within the
SCN, pre-parasympathetic and pre-sympathetic neurons (Buijs
et al., 2003), synapse onto the PVN which result in insulin release
from the pancreas (Kalsbeek et al., 2011) and glucose production
in the liver (Kalsbeek et al., 2004), respectively. Importantly, the
balance between the autonomic system and the rhythms of glucose
production and glucose uptake across the active and rest phases
results in steady plasma glucose levels and a shifting fuel to the
peripheral tissues when it is needed.
Furthermore, the SCN may also control glucose metabolism
through two-way communication with the ARC. Indeed, the SCN
synapses onto both the POMC and NPY/AgRP expressing neurons
in the ARC (Froy, 2010). The SCN itself also expresses receptors for
both leptin and ghrelin (Guan et al., 1997; Saper et al., 2005; Zigman et al., 2006) raising the possibility that these hormones may
directly regulate the SCN in a manner similar to their regulation on
the ARC. Furthermore, NPY from the intergeniculate leaflet (Harrington, 1997) and 5HT from the raphe nuclei have been shown
to modulate SCN signaling (Challet, 2007). While it is unknown if
nutrient signals can act within the SCN, changes in AMPK activity
can phosphorylate the core circadian gene, cryptochrome 1 (Cry1)
and lead to a lengthening of endogenous circadian period within
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FIGURE 3 | The SCN sends timing information to the brain and periphery.
The SCN derives “time of day” information from environmental light cues
received by specialized cells within the retina (Panda et al., 2002b) and
transferred to the SCN by the retinohypothalamic tract. The SCN then conveys
timing information to the brain including the PVN, ARC, subparaventricular

peripheral tissues (Lamia et al., 2009). It is important to point out
that as metabolic pathways change with obesity (e.g., rising leptin
levels), these changes can feedback to the SCN and lead to rhythm
changes. These rhythm changes, in turn, could result in circadian
disruption.
An increasing body of literature highlights the link between
circadian disruption and disease including cardiovascular disease,
Alzheimer’s, cancer, reproductive dysfunction, and important for
this review, T2DM (Tenkanen et al., 1998; Morikawa et al., 2005;
Boivin et al., 2007; Haupt et al., 2008; Rüger and Scheer, 2009;
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zone (SPZ), MPOA, intergeniculate leaflet (IGL), and paraventricular nucleus of
the thalamus (Kalsbeek et al., 2004, 2008; Froy, 2010; Stenvers et al., 2012).
The SCN also provides timing cues to peripheral tissues via the autonomic
nervous system and hormones, which together organize complex behaviors
from the sleep/wake to the feeding/fasting rhythm.

Wang et al., 2011). Many of the metabolic links to circadian disruption have not yet defined clear mechanisms of action but several
correlational studies have been performed. For example, nightshift workers exhibit shifted glucose and insulin rhythms (Simon
et al., 2000) and have a moderately higher risk of developing T2DM
compared to their day-shift equivalents (Wang et al., 2011). In
addition, eating during the wrong time of day has been linked
to weight gain and impaired glucose metabolism (Bazotte et al.,
1989; Colles et al., 2007; Salgado-Delgado et al., 2008; Arble et al.,
2009; Fonken et al., 2010). The use of genetic models has greatly
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progressed our mechanistic understanding of the link between
circadian rhythms and metabolism. One of the first circadian and
metabolic models was that of the Clock mutant mouse, which has
a mutation in a core circadian gene, Clock. This mouse displays
elevated body weight, fat mass, glucose, leptin, and lipid profiles
(Turek et al., 2005). Mutation of other core circadian genes has
also been linked to glucose metabolism. Mutation of the gene,
brain, and muscle aryl hydrocarbon receptor nuclear translocator
(ARNT-like 1 or BMAL1), only within pancreatic β-cells results
in decreased plasma insulin levels, elevated fasting glucose levels,
and an overall imbalance to glucose metabolism (Marcheva et al.,
2010). Whereas knockout of BMAL1 specifically in the liver leads
to hypoglycemia (Lamia et al., 2008). Knockout of the core circadian genes Cry1 and Cry2 results in elevated glucose and glucose
intolerance (Zhang et al., 2010). Interestingly, over-expression of
Cry improves glucose tolerance in otherwise insulin resist and
glucose intolerant db/db mice (Zhang et al., 2010). These studies
highlight the interconnected pathways between the circadian and
metabolic system at the cellular and genetic level.
Taken together, the circadian system has a prominent effect on
glucose metabolism. Working primarily through the ANS to generate daily rhythms in glucose parameters, the SCN, and circadian
rhythms are also integrated to metabolic pathways at the brain,
tissue, cellular, and genetic level.
IMPLICATION FOR TREATMENT

It is important to consider that many humans who experience
circadian disruption due to shift work or altered sleep patterns,
also consume high fat diets. While each of these challenges alone
are known to affect glucose metabolism, it is possible that the
combined effect of the two challenges are larger and more detrimental to glucose and/or overall health than the sum of each
single factor. For example, merely consuming a high fat diet is
known to alter the endogenous circadian clock resulting in a
lengthened circadian rhythm and a delay in the expression of
clock and clock controlled genes (Kohsaka et al., 2007). Similarly,
some studies indicate that circadian disruption can increase fat
consumption (Lowden et al., 2010). Thus, a feed-forward loop
between high fat diets and circadian disruption could work in
an additive manner to propagate metabolic disease. For effective treatment, knowledge of not only the single isolated stressor,
but also the interactive properties of that stressor would be ideal.
By specifically targeting the source of glucose homeostasis, CNS
treatment could present novel and more efficacious treatment
options.
A major limitation to targeting the CNS for treatment of
obesity and/or T2DM is that in some signaling systems, CNS
action may have opposite downstream metabolic effects. Two
T2DM therapeutics have this problem: insulin, and glibenclamide.
Although CNS insulin action is catabolic, T2DM patients gain
weight as a result of insulin treatment. This likely results from
the balance of the anorexigenic action of the hormone within the
CNS (Woods et al., 1979) versus its potent stimulatory effect on
fatty acid synthesis in the periphery (Porte et al., 2005). Glibenclamide, which inhibits KATP channels and results in an increase
in insulin secretion, acts centrally to cause hepatic insulin resistance (Pocai et al., 2005a). The fact that this drug is an effective
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hypoglycemic agent suggests the peripheral action sufficiently
counteracts its actions within the CNS. One last class of therapeutics worthy of mention is thiazolidinediones which function
as insulin sensitizers. The problem with thiazolidinediones is
slightly different in that its central and peripheral actions are
the same and function to both improve glucose homeostasis (Lu
et al., 2011), however, they also function to increase adiposity
(Lu et al., 2011; Ryan et al., 2011). To counteract the undesirable
effects of a single treatment, one option is to use a combination
of therapeutics that would be more effective at treating obesity.
Another form of combined therapeutics that is being increasingly explored is designed to target both obesity and glucose
homeostasis.
Interestingly, bariatric surgery is one form of combined therapy for both obesity and T2DM. Bariatric surgery has long been
linked with sustained weight loss and recent research highlights
the ability of bariatric surgery to act as an independent treatment of metabolic disease including T2DM (Cummings, 2012).
Indeed, bariatric surgeries such as RYGB and VSG are now being
referred to as “metabolic surgeries” in reference to their efficiency
in alleviating T2DM quickly and before substantial weight loss. It
is hypothesized that such metabolic surgeries may directly affect
the brain via the gut-brain axis that in turn can influence HGP.
For example, duodenal-jejunal bypass surgery has been shown
to lower glucose concentration by increasing nutrient flow across
the nutrient sensing jejunum. Indeed, this increased nutrient signaling was shown to lead to a decrease in glucose via it action
on the CNS (Breen et al., 2012). Bariatric surgery also leads to
increases in postprandial CCK and GLP-1 which, as described
previously, can regulate glucose metabolism (Rhee et al., 2012).
Moreover, there is some research, although limited, which links
bariatric surgery to circadian organization (Colles and Dixon,
2006; Michalaki et al., 2009; Stearns et al., 2009), further suggesting the gut-brain connection and how it can also influence the
SCN.
However, the costs and invasiveness of bariatric surgeries
prevents wide implementation and thus, additional treatment
options are necessary. In principle, as circadian disruption has
now been extensively linked to metabolic dysfunction, future
treatment advances could use combined therapies that target
both circadian disruption and obesity. Chronotherapy, which
traditionally refers to utilizing the time of administration to
optimize treatment, can now refer to targeting the circadian
system as a form of treatment. Melatonin, for example, plays
a key role in regulating circadian rhythms and also positively
effects metabolism by increasing triglyceride clearance (Garaulet
and Madrid, 2010). Additionally, quick release bromocriptine,
a dopamine 2 receptor agonist, has recently been approved by
the FDA for treatment of T2DM. Interestingly, bromocriptine
is only effective if taken in the morning upon awakening and is
hypothesized to work via the circadian system to substantially
reduce and regulate daily glucose levels in T2DM (Kerr et al.,
2010).
Thus, the CNS is clearly important in regulating glucose homeostasis under various physiological challenges including stress,
meals, and circadian variations. Further, environmental pressures
such as high fat diets and circadian disruptions alter the ability
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of the CNS orchestrate the peripheral organs to maintain glucose
levels. We hypothesize that this contributes to the onset of T2DM.
An increased understanding of how glucose metabolism responds
to environmental challenges can lead to new treatments. Indeed,
strides are currently being made to develop combination treatments that target both the cause and the symptoms of impaired
glucose metabolism.
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